Additionally, CXCL11 is significantly overexpressed in the serum of pretreated PaC patients and differentially expressed in response to gemcitabine and erlotinib treatment, indicating its potential as both a diagnostic and predictive biomarker for PaC33. Here, CXCL11 is linked to gonorrhea.